Is weight loss on Wegovy permanent, or does it come back?

What happens to weight after people stop taking Wegovy?

The clearest answer comes from the STEP 1 extension study, which followed participants for a year after they stopped semaglutide 2.4mg. On average, roughly two-thirds of the weight lost during the treatment phase was regained within 12 months of stopping. That is a significant reversal — but not a complete one. Participants still weighed less, on average, than they did before starting.

This pattern is not unique to semaglutide. It mirrors what has been seen across the class of GLP-1 medicines and reflects the underlying biology of obesity: appetite-regulating hormones and metabolic set points do not permanently reset after a course of treatment. Once the medicine is withdrawn, those signals reassert themselves.

The STEP 1 trial itself, published in the New England Journal of Medicine, reported around 15% average body-weight reduction at 68 weeks on 2.4mg semaglutide alongside lifestyle changes. Understanding how much of that holds after stopping is central to any honest conversation about treatment.

Worth checking the full picture on Wegovy and weight loss if you want the trial numbers in more detail.

Does continuing Wegovy long-term keep the weight off?

The evidence suggests yes, while the medicine is being taken and tolerated. Continued use at the maintenance dose maintains appetite suppression and the hormonal signalling that slows gastric emptying and reduces caloric intake. Weight tends to stabilise rather than fall indefinitely, but it does not rebound in the way it does after stopping.

This is why obesity specialists increasingly frame treatment as ongoing rather than a fixed course. The NHS medicines information for semaglutide confirms the licensed use is alongside a reduced-calorie diet and increased physical activity, the medicine works with lifestyle changes, not instead of them.

On the NHS, NICE's recommendation for Wegovy (TA875) specifies a maximum of two years' use within a specialist weight management service. That two-year cap is an NHS commissioning boundary, not a clinical ceiling on safety, private prescribing can run longer, subject to regular clinical review and continued response. If less than 5% weight loss has been achieved at six months on the maintenance dose, continuing is unlikely to be appropriate.

The research on semaglutide and weight outcomes covers the long-term trial data in more depth.

Is lifestyle change enough to hold the weight after stopping?

For some people, partially. Dietary habits built during treatment, alongside sustained physical activity, can slow regain. But the biology tends to dominate. Hunger signals that were suppressed by semaglutide return, appetite increases, and energy expenditure adjusts downward, a combination that makes maintaining a large deficit difficult without pharmacological support.

That is not a counsel of despair. People who regain weight after stopping are not back to square one in terms of metabolic risk markers, fitness, or the habits they have built. Some clinicians describe the treatment period as an opportunity to embed sustainable behaviours, rather than a permanent fix in itself.

One question our prescribers hear regularly: whether switching from the injection to a different formulation changes this picture. The once-daily Wegovy tablet (oral semaglutide, approved by the MHRA in June 2026) acts through the same mechanism, so the same biology around stopping applies. You can read more about how the Wegovy tablet compares if you are weighing up formulations. Separately, people exploring how quickly weight tends to shift on Wegovy often find the week-by-week breakdown useful context.

What does this mean for deciding how long to take Wegovy?

It means duration is a clinical question, not a commercial one. Your prescriber will look at how your weight has responded, your starting conditions, any side effects, and your overall health goals. For many people with significant weight-related conditions, the risk calculation favours continued treatment; for others, a defined course followed by careful monitoring makes sense.

The current guide to Wegovy as a treatment option covers what a prescriber considers when reviewing suitability. Private treatment through a service like ours involves a real clinician reading your consultation (a named prescriber, not software) before anything is prescribed, and again before every repeat order. There are no auto-renewals; every continuation is reviewed on its own merits.

If you would like to explore whether Wegovy is the right weight management medicine for your situation, you can speak to our prescribers through a free consultation, no commitment, just a clinical assessment.